How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,365 results for

adhd Cognitive behavioural therapy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)

: Targacept Inc. ClinicalTrials.gov Identifier: Other Study ID Numbers: TC-5619-238-CRD-004 First Posted: November 17, 2011 Last Update Posted: April 30, 2013 Last Verified: April 2013 Keywords provided by Targacept Inc.: ADHD Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations (...) : November 17, 2011 Last Update Posted : April 30, 2013 Sponsor: Targacept Inc. Information provided by (Responsible Party): Targacept Inc. Study Details Study Description Go to Brief Summary: Study is to assess if TC-5619 improves symptoms for adults diagnosed with the inattentive-predominant subtype of ADHD over a 4-week treatment period. Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: TC-5619-238 5mg Drug: TC-5619-238 25mg Drug: Placebo Phase 2 Detailed

2011 Clinical Trials

182. Genetic Modulation of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)

of Functional Brain Activity of Attention-deficit/Hyperactivity Disorder-related Working Memory Processes Study Start Date : May 2011 Actual Primary Completion Date : December 2012 Actual Study Completion Date : March 2013 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: methylphenidate, non-retard Drug: Methylphenidate, non-retard Medication (methylphenidate, non-retard) will be titrated (...) information Responsible Party: Martin Herrmann, Principal Investigator, Wuerzburg University Hospital ClinicalTrials.gov Identifier: Other Study ID Numbers: W004PS0108_1 First Posted: May 10, 2011 Last Update Posted: December 10, 2014 Last Verified: December 2014 Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Methylphenidate Central Nervous System

2011 Clinical Trials

183. Guided Self-Help for Parents of Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

of Cologne Collaborator: Eli Lilly and Company Information provided by (Responsible Party): Manfred Doepfner, University of Cologne Study Details Study Description Go to Brief Summary: Cognitive-behavioral based guided self-help for parents of children with Attention-Deficit/Hyperactivity Disorder (ADHD) is investigated in a feasibility and effectiveness study. The treatment is offered under routine-care conditions of the health-care system in Germany. Practicability, treatment participation (...) Identifier: Other Study ID Numbers: ADHD-TEAM-01 First Posted: May 10, 2011 Last Update Posted: April 15, 2014 Last Verified: April 2014 Keywords provided by Manfred Doepfner, University of Cologne: Program Evaluation ADHD Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations

2011 Clinical Trials

184. Train Your Brain and Exercise Your Heart? Advancing the Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

for treating ADHD. The primary outcome measure is behaviour (symptoms of ADHD). Secondary outcome measures include neurocognition and cortical regulation. This research project will give answer to the question if neurofeedback and exercise are as effective as MPH. Furthermore, it will give insight in how these interventions will give rise to improvements in behavior. Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder (ADHD) Other: Neurofeedback Behavioral: Exercise (...) neurofeedback exercise neurophysiology Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators

2011 Clinical Trials

185. Long-term Effects of Medication for ADHD

to Layout table for study information Study Type : Observational Estimated Enrollment : 100 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Long-term Effects of Medication for Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents on Cognition, Everyday Function and Quality of Life Study Start Date : April 2014 Estimated Primary Completion Date : December 2019 Estimated Study Completion Date : December 2019 Resource links provided (...) Edition Scale; CHIP-CE) during 24 months of ADHD treatment. Condition or disease Attention Deficit Disorder With Hyperactivity Detailed Description: Single-centre open-label prospective study, including 100 subjects over a period of 2 years. Children and adolescents (6-17 years) who have been diagnosed with ADHD will be enrolled and followed during 24 months of ADHD treatment. Screening assessments include medical, neurodevelopmental and psychiatric history, clinical evaluation and definition

2017 Clinical Trials

186. Principles of Pediatric Patient Safety: Reducing Harm Due to Medical Care

in office care (7%); together, these errors comprised 80% of all reports. In this practice, a voluntary, nonpunitive, multidisciplinary team approach was effective in improving error reporting, investigating causes of reported errors, and implementing safety promotion strategies. In addition to these setting-specific errors, the National Academies of Sciences, Engineering, and Medicine has turned attention to diagnostic decision-making as perhaps the most frequent source of medical error. Errors (...) the standardization of concentrations in compounded medications; developing, spreading, and advocating for pediatric-specific health care information technology for drug delivery; educating providers on methods to reduce medication errors, including medication reconciliation; ensuring that providers maintain access to and proficiency in the use of a comprehensive and current pharmaceutical knowledge base; and creating policies that advocate for safe medication delivery to children in all health care settings

2019 American Academy of Pediatrics

187. How do stimulant treatments for ADHD work? Evidence for mediation by improved cognition. (Abstract)

How do stimulant treatments for ADHD work? Evidence for mediation by improved cognition. Stimulant medications such as methylphenidate (MPH) are the frontline treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). Despite their well-documented efficacy, the mechanisms by which stimulants improve clinical outcomes are not clear. The current study evaluated whether MPH effects on classroom behavior were mediated by improved cognitive functioning.Children with ADHD (n = 82; 9-12 years old (...) (forward and backward spatial span). Clinical outcomes included math seatwork productivity and teacher-rated classroom behavior. A within-subjects path-analytic approach was used to test mediation. MPH-placebo and dose-response contrasts were used to evaluate drug effects.Methylphenidate improved seatwork productivity and teacher ratings (ds = 1.4 and 1.1) and all domains of cognition (ds = 0.3-1.1). Inhibitory control (Stop Signal Task, SST) and working memory backward uniquely mediated the effect

2018 Journal of Child Psychology and Psychiatry Controlled trial quality: uncertain

188. Long-term effects of stimulant treatment on ADHD symptoms, social-emotional functioning, and cognition. Full Text available with Trip Pro

Long-term effects of stimulant treatment on ADHD symptoms, social-emotional functioning, and cognition. Methodological and ethical constraints have hampered studies into long-term lasting outcomes of stimulant treatment in individuals with attention-deficit/hyperactivity disorder (ADHD). Lasting effects may be beneficial (i.e. improved functioning even when treatment is temporarily ceased) or detrimental (i.e. worse functioning while off medication), but both hypotheses currently lack empirical (...) support. Here we investigate whether stimulant treatment history predicts long-term development of ADHD symptoms, social-emotional functioning or cognition, measured after medication wash-out.ADHD symptoms, social-emotional functioning and cognitive test performance were measured twice, 6 years apart, in two ADHD groups (stimulant-treated versus not stimulant-treated between baseline and follow-up). Groups were closely matched on baseline clinical and demographic variables (n = 148, 58% male, age

2018 Psychological Medicine

189. Sluggish Cognitive Tempo as a Possible Predictor of Methylphenidate Response in Children With ADHD: A Randomized Controlled Trial. Full Text available with Trip Pro

Sluggish Cognitive Tempo as a Possible Predictor of Methylphenidate Response in Children With ADHD: A Randomized Controlled Trial. To examine whether sluggish cognitive tempo (SCT) symptomatology moderates dose response to methylphenidate and whether the impact of SCT on medication response is distinct from attention-deficit/hyperactivity disorder (ADHD) subtype effects.Stimulant-naive children with ADHD predominantly inattentive type (ADHD-I; n = 126) or ADHD combined type (ADHD-C; n = 45 (...) as methylphenidate responders, methylphenidate nonresponders, or placebo responders by 2 blinded physicians and (2) parent and teacher ratings of child behavior on the Vanderbilt ADHD Diagnostic Rating Scales while subjects were on treatment with placebo or 1 of 3 methylphenidate dosages (low, medium, high).Increased SCT Sluggish/Sleepy factor scores were associated with being a methylphenidate nonresponder or placebo responder rather than a methylphenidate responder (P = .04). Sluggish/Sleepy factor scores were

2018 Journal of Clinical Psychiatry Controlled trial quality: predicted high

190. Added Value of the Oculomotor and Cognitive Examination in the Management of Patients With ADHD

Verified: January 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Fabrice Duval, Centre Hospitalier Rouffach: oculomotor performances neurocognition methylphenidate Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive (...) (10 mg orally,V1) and during the follow-up visit at 6 months (V2). Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: Methylphenidate Oral Tablet Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 90 participants Intervention Model: Single Group Assignment Intervention Model Description: Interventional study designed to evaluate routine care. The patients

2018 Clinical Trials

191. Thinking Skills at Work: Cognitive Remediation Therapy for Patients With Serious Mental Illness

weeks. Clients will be assessed at 3-time points: prior to the start of cognitive remediation ("baseline"), end-point (3-month), and 6 months after the endpoint evaluation. Primary outcome measures will include success at gaining a competitive job, total hours of competitive employment, and neuropsychological measures of cognition. Condition or disease Intervention/treatment Phase Schizophrenia and Related Disorders Psychotic Disorder Behavioral: Cognitive Remediation Therapy Not Applicable Detailed (...) , 2018 Last Update Posted: April 10, 2018 Last Verified: April 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Fraser Health: Cognitive Remediation Therapy Additional relevant MeSH terms: Layout table for MeSH terms Disease Schizophrenia Mental Disorders Psychotic Disorders Pathologic Processes Schizophrenia Spectrum and Other Psychotic Disorders

2018 Clinical Trials

192. Cross‐species studies of cognition relevant to drug discovery: a translational approach Full Text available with Trip Pro

Cross‐species studies of cognition relevant to drug discovery: a translational approach This review advances the case that bidirectional, cross-species translation of findings from experimental animals to and from humans is an important strategy for drug discovery. Animal models of mental disorders require appropriate behavioural or cognitive outcome variables that can be generalized cross-species. One example is the treatment of impulsive behaviour in attention deficit hyperactivity disorder (...) inhibitor citalopram on probabilistic learning and reversal (upon which atomoxetine has little effect) will also be reviewed, possibly relevant to the treatment of clinical depression, Finally, other promising examples of parallel studies of behavioural effects of CNS-active drugs in animals and humans will also be described. Linked Articles This article is part of a themed section on Pharmacology of Cognition: a Panacea for Neuropsychiatric Disease? To view the other articles in this section visit http

2017 British journal of pharmacology

193. MAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs Full Text available with Trip Pro

MAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs Impairments in attention and inhibitory control are endophenotypic markers of neuropsychiatric disorders such as schizophrenia and represent key targets for therapeutic management. Robust preclinical models and assays sensitive to clinically relevant treatments are crucial for improving cognitive enhancement strategies.We assessed a rodent model with neural and behavioral (...) on performance across all animals. Donepezil (0.1-1 mg/kg) showed near-significant enhancements in d', and EVP-6124 (0.3-3 mg/kg) exerted no effects in the rCPT paradigm.The MAM-E17 model exhibits robust and replicable impairments in rCPT performance that resemble attention and inhibitory control deficits seen in schizophrenia. Pharmacological profiles were highly consistent with known drug effects on cognition in preclinical and clinical studies. The rCPT is a sensitive and reliable tool with high

2017 Psychopharmacology

194. Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia. Full Text available with Trip Pro

Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia. One prominent, long-standing view is that individuals with schizophrenia smoke cigarettes more than the general population to "self-medicate" cognitive deficits and other symptoms. This study tested the self-medication hypothesis by examining the effects of smoking abstinence and resumption on cognition in patients with schizophrenia. Nicotine (...) for multiple comparisons. Surprisingly, in this within subject "On-Off-Off-On" design, there were no significant effects of early or prolonged abstinence from smoking on cognitive and behavioral measures in smokers with schizophrenia. The results of this study challenge the widely held "self-medication" hypothesis of smoking and schizophrenia, question the extent of pro-cognitive effects of smoking and nicotine in schizophrenia, and support encouraging smoking cessation in schizophrenia.Published

2017 Schizophrenia Research

195. Effects of Self-monitoring Technique on Inattentive Behaviors of Students with Attention Deficit Hyperactivity Disorder Full Text available with Trip Pro

Effects of Self-monitoring Technique on Inattentive Behaviors of Students with Attention Deficit Hyperactivity Disorder Beneficial effects of stimulants on core symptoms of Attention Deficit Hyperactivity Disorder (ADHD) have been reported in several studies. Behavioral interventions have also been proposed as empirically supported interventions for ADHD. Although cognitive-behavioral therapies (CBT) have been criticized for the lack of evidence-based data, some studies have indicated (...) the positive effects of CBT techniques on children with attention deficit hyperactivity disorder (ADHD). This article reports the effects of self-monitoring technique, as a CBT technique, on inattentive behaviors of children with ADHD.

2011 Iranian journal of psychiatry

196. Behavioural and cognitive?behavioural group?based parenting programmes for early?onset conduct problems in children aged 3 to 12 years Full Text available with Trip Pro

tend to exist on a continuum of severity ( ; ). Children with the most severe disruptive behaviours may be diagnosed with Conduct Disorder (CD) or Oppositional Defiant Disorder (ODD) (see Diagnostic and Statistical Manual of Mental Disorders IV (DSM‐IV 2000)). Conduct problems are three to four times more likely to be present in boys than girls and can develop into CD if left untreated ( ); they are also sometimes comorbid with Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity (...) (CD) or Oppositional Defiant Disorder (ODD) as well as scoring above the clinical cut‐off point on a validated questionnaire ( ; ; Barkley 2000; ; ; ). Five studies reported a low level of comorbidity with Attention Deficit Hyperactive Disorder (ADHD) ( ; ; Barkley 2000; ; ). Seven studies were based on population samples characterised by high levels of socioeconomic disadvantage ( ; Barkley 2000; ; ; ; ; ). All but one of the remainder included samples whose socioeconomic status was comparable

2012 Campbell Collaboration

197. Transdiagnostic, Cognitive and Behavioral Intervention for in School-aged Children With Emotional and Behavioral Disturbances

and Behavioral Therapies Children and Adolescents Community Health Care Early Intervention Additional relevant MeSH terms: Layout table for MeSH terms Disease Anxiety Disorders Depressive Disorder Depression Conduct Disorder Attention Deficit and Disruptive Behavior Disorders Problem Behavior Pathologic Processes Mental Disorders Mood Disorders Behavioral Symptoms Neurodevelopmental Disorders (...) in children and adolescents and mark a three-fold increased risk of mental disorder in young adulthood. Evidence-based psychological interventions are recommended for indicated prevention and first-line treatment, but access to treatment is often limited. A new, modular cognitive and behavioural therapy program Mind My Mind (MMM) comprising evidence-based interventions for children with emotional and behavioral problems was designed to be delivered by educational psychologists in the Danish municipalities

2018 Clinical Trials

198. Cognitive Therapy for Depression

theory also focuses on information processing deficits, selective attention, and memory biases toward the negative. Essence of therapy : In cognitive therapy (CT), clients are taught cognitive and behavioral skills so they can develop more accurate/helpful beliefs and eventually become their own therapists. Length : In most randomized clinical trials or efficacy trials, CT for depression is typically delivered over 8 to 16 sessions. There is a significant interaction between initial symptom severity (...) Belmont Avenue, Suite #700, Bala Cynwyd, PA 19004) Contact : (610) 664-3020 : Supporting Professionals, Educating Consumers, and Connecting Individuals with Truly Effective Care (Multiple locations worldwide) Workshops under the direction of Judith Beck, PhD at the Beck Institute for the annual conference of the Association for Behavioral and Cognitive Therapies (ABCT) Measures, Handouts and Worksheets Self-help Books (2nd Edition, Greenberger, Padesky, & Beck) (Burns) Important Note: The books listed

2014 Society of Clinical Psychology

199. Internet-Based Cognitive Behavioral Therapy for Adults With ADHD in Outpatient Psychiatric Care: A Randomized Trial. Full Text available with Trip Pro

Internet-Based Cognitive Behavioral Therapy for Adults With ADHD in Outpatient Psychiatric Care: A Randomized Trial. The purpose of the study was to evaluate an Internet-based cognitive behavioral therapy (iCBT) program targeting difficulties and impairments associated with adult ADHD.Forty-five adults diagnosed with ADHD were randomized to either self-help (iCBT self-help format [iCBT-S]), self-help with weekly group sessions (iCBT group-therapy format [iCBT-G]), or a waiting-list control (...) group. Treatment efficacy was measured at pre- and posttreatment and at 6-month follow-up.Intention-to-treat (ITT) analysis showed a significant reduction in ADHD symptoms for the iCBT-S group in comparison with the waiting-list controls at posttreatment, with a between-group effect size of d = 1.07. The result was maintained at 6-month follow-up. No significant difference was found at posttreatment or 6-month follow-up between the iCBT-S and iCBT-G groups.The findings show that a CBT treatment

2014 Journal of attention disorders Controlled trial quality: uncertain

200. Protocol for a proof of concept randomized controlled trial of cognitive-behavioural therapy for adult ADHD as a supplement to treatment as usual, compared with treatment as usual alone. Full Text available with Trip Pro

Protocol for a proof of concept randomized controlled trial of cognitive-behavioural therapy for adult ADHD as a supplement to treatment as usual, compared with treatment as usual alone. ADHD is prevalent in adults and frequently associated with impairment and distress. While medication is often the first line of treatment a high proportion of people with the condition are not fully treated by medication alone, cannot tolerate medication or do not wish to take it. Preliminary studies suggest (...) that psychosocial approaches are a promising adjunctive or alternative treatment option. To date, individual cognitive-behaviour therapy (CBT) has been found to be efficacious in three randomized controlled trials (RCTs). There is a need for more RCTs to be carried out in order to replicate these results in different sites, to further investigate the acceptability and feasibility of CBT in this population and to further develop CBT approaches based on a psychological model. This randomized controlled trial

2014 BMC psychiatry Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>